Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 9, 2016 - Issue 1
Submit an article Journal homepage
572
Views
21
CrossRef citations to date
0
Altmetric
Drug Profiles

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

Paul G RichardsonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
,
R Donald HarveyWinship Cancer Institute, Emory University, Atlanta, GA, USA
,
Jacob P LaubachDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
,
Philippe MoreauHematology Department, University Hospital, Nantes, France
,
Sagar LonialWinship Cancer Institute, Emory University, Atlanta, GA, USA
&
Jesús F San-MiguelCIMA, IDISNA, Clínica Universidad de Navarra, Pamplona, Spain
Pages 35-48 | Published online: 26 Oct 2015

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jacob P. Laubach, Jesus F. San-Miguel, Vania Hungria, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Melissa Alsina & Paul G. Richardson. (2017) Deacetylase inhibitors: an advance in myeloma therapy?. Expert Review of Hematology 10:3, pages 229-237.
Read now

Articles from other publishers (20)

Jiangkun Yan, Kairui Yue, Xuejing Fan, Ximing Xu, Jing Wang, Mengting Qin, Qianer Zhang, Xiaohan Hou, Xiaoyang Li & Yong Wang. (2023) Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors. European Journal of Medicinal Chemistry 246, pages 115004.
Crossref
Monica Epstein & Candis Morrison. (2022) Practical guidance for new multiple myeloma treatment regimens: A nursing perspective. Seminars in Oncology 49:1, pages 103-117.
Crossref
Yanchun Li, Jishun Quan, Haoxuan Song, Dongzhu Li, Enlong Ma, Yanjuan Wang & Chao Ma. (2021) Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. Bioorganic Chemistry 114, pages 105081.
Crossref
Kunal Nepali & Jing-Ping Liou. (2021) Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science 28:1.
Crossref
Jacob P Laubach, Fredrik Schjesvold, Mário Mariz, Meletios A Dimopoulos, Ewa Lech-Maranda, Ivan Spicka, Vania T M Hungria, Tatiana Shelekhova, Andre Abdo, Lutz Jacobasch, Chantana Polprasert, Roman Hájek, Árpád Illés, Tomasz Wróbel, Anna Sureda, Meral Beksac, Iara Z Gonçalves, Joan Bladé, S Vincent Rajkumar, Ajai Chari, Sagar Lonial, Andrew Spencer, Pierre Maison-Blanche, Philippe Moreau, Jesus F San-Miguel & Paul G Richardson. (2021) Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. The Lancet Oncology 22:1, pages 142-154.
Crossref
Yufeng Xiao & Xuan Zhang. (2020) Recent advances in small molecular modulators targeting histone deacetylase 6. Future Drug Discovery 2:4.
Crossref
Tao Liang, Xuben Hou, Yi Zhou, Xinying Yang & Hao Fang. (2019) Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors. ACS Medicinal Chemistry Letters 10:8, pages 1122-1127.
Crossref
Veronika A. Myasoedova, Vasily Sukhorukov, Andrey V. Grechko, Dongwei Zhang, Elena Romanenko, Vawain Orekhov & Alexander N. Orekhov. (2019) Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Current Pharmaceutical Design 25:6, pages 635-641.
Crossref
Fang-I Huang, Yi-Wen Wu, Ting-Yi Sung, Jing-Ping Liou, Mei-Hsiang Lin, Shiow-Lin Pan & Chia-Ron Yang. (2019) MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Frontiers in Oncology 9.
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Mohammad Alzrigat, Helena Jernberg-Wiklund & Jonathan Licht. (2018) Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity. Epigenomes 2:3, pages 16.
Crossref
Matthias Schiedel & Stuart J Conway. (2018) Small molecules as tools to study the chemical epigenetics of lysine acetylation. Current Opinion in Chemical Biology 45, pages 166-178.
Crossref
Hsueh-Yun Lee, Kunal Nepali, Fang-I Huang, Chih-Yi Chang, Mei-Jung Lai, Yu-Hsuan Li, Hsiang-Ling Huang, Chia-Ron Yang & Jing-Ping Liou. (2018) ( N -Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo . Journal of Medicinal Chemistry 61:3, pages 905-917.
Crossref
Arianna BottoniLara RizzottoTzung-Huei LaiChaomei Liu, Lisa L. SmithRose MantelSean ReiffDalia El-GamalKarilyn LarkinAmy J. JohnsonRosa LapalombellaAmy Lehman, William Plunkett, John C. ByrdJames S. BlachlyJennifer A. WoyachDeepa Sampath. (2016) Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood 128:26, pages 3101-3112.
Crossref
Vanita Chopra, Luisa Quinti, Prarthana Khanna, Paolo Paganetti, Rainer Kuhn, Anne B. Young, Aleksey G. Kazantsev & Steven Hersch. (2016) LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease. Journal of Huntington's Disease 5:4, pages 347-355.
Crossref
Leonard Naymagon & Maher Abdul-Hay. (2016) Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology & Oncology 9:1.
Crossref
Peter Atadja & Lawrence Perez. 2016. Successful Drug Discovery. Successful Drug Discovery 59 88 .
Jesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A Dimopoulos, Ashraf Elghandour, Wieslaw W Jedrzejczak, Andreas Günther, Thanyaphong N Nakorn, Noppadol Siritanaratkul, Robert L Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae H Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Florence Binlich & Paul G Richardson. (2016) Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. The Lancet Haematology 3:11, pages e506-e515.
Crossref
Andrew J. Wilson, Kofi Sarfo-Kantanka, Toby Barrack, Alexandra Steck, Jeanette Saskowski, Marta A. Crispens & Dineo Khabele. (2016) Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Gynecologic Oncology 143:1, pages 143-151.
Crossref
C.A. Zahnow, M. Topper, M. Stone, T. Murray-Stewart, H. Li, S.B. Baylin & R.A. CaseroJr.Jr.. 2016. 55 111 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.